Amplia Therapeutics Ltd Adds Brett Carter to Board as Narmafotinib Advances
Amplia strengthens board with appointment of biopharma dealmaker Brett Carter
Amplia Therapeutics (ASX:ATX, OTCQB:INNMF) has appointed Mr Brett Carter as Non-Executive Director, effective 6 July 2026. The appointment adds seasoned global oncology dealmaking experience to the Board.
The timing is strategic. Carter joins as Amplia’s lead drug narmafotinib progresses into later-stage development.
With more than 25 years’ global experience across oncology drug development, corporate strategy and business development, Carter brings expertise directly relevant as the Company positions for potential licensing or partnering discussions.
When big ASX news breaks, our subscribers know first
Who is Brett Carter?
Carter is an experienced biopharmaceutical executive with a track record spanning major global markets. His career highlights include:
-
More than 25 years’ global experience across oncology drug development, corporate strategy and business development
-
11 years with GSK in London, including as a director in the global corporate transactions team, leading and supporting licensing, acquisition, investment and divestment deals across Europe, Asia and the United States
-
Former CEO of the Cancer Therapeutics Cooperative Research Centre (CTx), where Amplia’s drug assets were discovered
-
While at CTx, involved in licensing an oncology programme to Pfizer in a deal valued up to $670 million
-
Currently COO of Melbourne-based Medicines Development for Global Health, a director of privately-held Greywolf Therapeutics Australia, and strategic adviser to various Australian life science companies
Carter holds an MBA from London Business School and a BSc from RMIT University, and is a graduate of the Australian Institute of Company Directors (GAICD).
Carter was previously CEO of the organisation where Amplia’s drug assets were discovered.
Ms Jane Bell AM, Board Chair
“I am delighted to welcome Brett to the Board at this exciting time in the Company’s development. His extensive experience in the structuring and negotiation of licensing, acquisition, investment and financing transactions across global pharmaceutical markets will be critical as Amplia’s lead drug narmafotinib progresses into later stage development.”
Why board expertise matters as narmafotinib advances
Narmafotinib (AMP945) is Amplia’s best-in-class inhibitor of Focal Adhesion Kinase (FAK), a protein over-expressed in pancreatic cancer and gaining increasing attention for its role in solid tumours.
The table below summarises Amplia’s clinical progress.
| Trial | Drug Combination | Indication | Key Result |
|---|---|---|---|
| ACCENT | Narmafotinib + gemcitabine + Abraxane | First-line advanced pancreatic cancer | 36% response rate (superior to chemotherapy alone); mOS 11.1 months |
| AMPLICITY | Narmafotinib + FOLFIRINOX | Advanced pancreatic cancer (Australian sites) | Ongoing |
The ACCENT trial has reported a response rate of 36%, described as superior to chemotherapy alone, alongside a median overall survival (mOS) of 11.1 months. The AMPLICITY trial continues at Australian sites.
The ACCENT trial results presented at the AACR annual meeting in San Diego confirmed an 8% complete response rate, compared to just 0.2% for standard chemotherapy alone, with independent central review validating the figures ahead of pivotal trial planning.
The next major ASX story will hit our subscribers first
What this means for investors
The appointment adds transaction and dealmaking capability to the Board at a pivotal clinical stage for narmafotinib. Carter’s experience structuring licensing and financing deals across global pharmaceutical markets complements the Company’s progression into later-stage development.
The announcement does not disclose remuneration, share grants, or any changes to board size.
Amplia remains focused on advancing its FAK-inhibitor pipeline across fibrotic cancers, including pancreatic and ovarian cancer, as well as fibrosis indications such as idiopathic pulmonary fibrosis (IPF).
For investors exploring the full breadth of the narmafotinib pipeline beyond pancreatic cancer, our dedicated guide to narmafotinib’s ovarian cancer expansion covers the PRROSE trial structure, the ANZGOG partnership arrangement, and the clinical rationale for targeting high-grade serous ovarian cancer patients who fail platinum-based chemotherapy.
Ready to Learn More About Narmafotinib’s Clinical Progress?
Amplia Therapeutics is advancing its best-in-class FAK inhibitor narmafotinib through later-stage development, with the ACCENT trial delivering a 36% response rate superior to chemotherapy alone — and Brett Carter’s global dealmaking expertise now strengthening the Board ahead of potential licensing discussions.
Explore Amplia’s full pipeline, clinical data, and corporate strategy by visiting the Amplia Therapeutics investor centre to assess the opportunity for yourself.